title: ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
authors.forename: A
authors.initials: A
authors.lastname: Ferrario
authors.forename: F
authors.initials: F
authors.lastname: Radaelli
authors.forename: M
authors.initials: M
authors.lastname: Goldaniga
authors.forename: F Grifoni
authors.initials: FG
authors.lastname: F
authors.forename: B
authors.initials: B
authors.lastname: Olivero
authors.forename: F
authors.initials: F
authors.lastname: Rossi
authors.forename: L
authors.initials: L
authors.lastname: Baldini
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D012008:Recurrence; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D000068877:Imatinib Mesylate